FDA
-
-
-
-
-
-
-
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
-
-
-
-
-
-
-
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
-
-
-
-
-
-
-
Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol
-
-
-
-
-
-
-
Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Abeona Therapeutics Announces Strategy Update and 2021 Financial Results
-
-
-
-
-
-
-
Avenue Therapeutics Stock Trading Halted Today
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

